You can buy or sell BEAM and other stocks, options, and ETFs commission-free!
Beam Therapeutics, Inc. develops and commercializes DNA base editing technologies for the treatment of human disease. Its licensed technology platform, which includes access to base editing technologies and associated technologies that enhance the scope of base editing. The company was founded by David R. Liu, Feng Zhang and J. Keith Joung on January 25, 2017 and is headquartered in Cambridge, MA. The listed name for BEAM is Beam Therapeutics Inc. Common Stock.
52 Week High
52 Week Low
— per share
-$0.69 per share